FIGURE 2.

Originator adalimumab list prices (in euro per unit) before loss of exclusivity (October 2018 or earlier) and originator adalimumab list prices and actual prices after loss of exclusivity (May 10, 2019) in the countries surveyed where actual prices were reported. Countries are grouped based on whether there was a change in list price. For Estonia no list price before loss of exclusivity was reported. For the Republic of Srpska no list prices were reported. H: hospital setting; AC: ambulatory care (retail).